macro

Capricor: FDA rejects Deramiocel application, citing insufficient evidence of effectiveness

The FDA issued a complete response letter (CRL) for the resubmitted Deramiocel application, citing insufficient evidence of effectiveness and other clinical deficiencies.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

According to TradingView, the US Food and Drug Administration issued a complete response letter (CRL) for the resubmitted BLA for Deramiocel. The agency cited insufficient evidence of effectiveness and other clinical shortcomings, even though HOPE-2 and HOPE-3 reportedly met their primary endpoints. The letter remains under review.

why it matters

For Capricor shares this is a negative regulatory signal, since the rejection pushes back any possible path to market for the drug. The report notes that available funds were expected to cover at least 12 months of planned operations, which reduces the immediate risk of a cash shortfall. Investors will be watching the company's next steps and its response to the letter.

market impact

Capricor shares (CAPR): the regulator's rejection puts pressure on the stock

  • Capricor shares (CAPR) pressure down — the FDA rejection delays the drug's path to market

tags

instruments

CAPR

on polymarket

sources

  1. CAPR: FDA issued a CRL for Deramiocel, citing insufficient evidence of effectiveness — TradingView, 21 November 2026 at 10:39 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗